MiR-146a como potencial biomarcador na doença degenerativa mixomatosa da válvula mitral do cão – delineamento experimental
Miniatura indisponível
Data
2023
Autores
Título da revista
ISSN da revista
Título do Volume
Editora
Resumo
A doença degenerativa mixomatosa da válvula mitral é a doença cardiovascular
adquirida mais comum em cães, sendo também a causa mais frequente de insuficiência
cardíaca. Esta patologia apresenta várias semelhanças com o prolapso da válvula mitral em
humanos. Como os meios de diagnóstico necessários nem sempre estão disponíveis,
biomarcadores como os microRNA são cada vez mais estudados como potenciais novas formas
de diagnóstico e terapêutica.
Este trabalho propôs-se a desenvolver um delineamento experimental para a extração e
medição da concentração de microRNA, neste caso o miR-146a, através de amostras de sangue,
que pudesse ser utilizado noutras investigações que tenham como propósito a análise de
microRNA no sangue.
Para tal, procedeu-se à recolha de amostras de sangue de 47 cães e à realização de
exames ecocardiográficos, após os quais foi possível dividir os animais em quatro grupos, o
grupo de controlo, estádio B1, B2 e C. As amostras foram recolhidas em duas fases, a primeira
foi desenvolvida entre 2020/2021 e a segunda entre 2021/2022.
Até à data, não foi possível obter os resultados da concentração do miR-146a das
amostras recolhidas durante a segunda fase, no entanto, as amostras da primeira fase do estudo
revelaram pela primeira vez uma relação entre este microRNA e a doença degenerativa
mixomatosa da válvula mitral em cães. Espera-se que os resultados da segunda fase corroborem
os da primeira.
Palavras-chave: doença mixomatosa da válvula mitral; protocolo experimental;
biomarcadores; miR-146a.
Trial design for extraction and measurement of microRNA concentration in blood samples. Myxomatous mitral valve disease is the most common acquired cardiovascular disease in dogs and the most frequent cause of heart failure. This pathology has various similarities with mitral valve prolapse in humans. And since complementary means of diagnosis aren’t always available, biomarkers like microRNA have started to be studied as a new potential way of diagnosing and treating these diseases. This project proposed to develop a trial design for extraction and measurement of microRNA concentrations, in this case miR-146a, using only blood samples, that could be used in future investigations that aim to analyze microRNA in blood samples. To this end, blood samples were collected, and echocardiographic examinations performed to 47 dogs that where then divided in four groups: control group, stage B1, B2 and C. The study was divided in two phases, the first phase took place between 2020/2021 and the second phase in 2021/2022. Till this date it was not yet possible to acquire miR-146a concentration results from the second phase samples, however the samples from the first phase of this study revealed for the first time a relation between this microRNA and myxomatous mitral valve disease in dogs. It is expected that the second phase results corroborate the first phase. Palavras-chave: Myxomatous mitral valve disease; trial design; biomarkers; miR-146a.
Trial design for extraction and measurement of microRNA concentration in blood samples. Myxomatous mitral valve disease is the most common acquired cardiovascular disease in dogs and the most frequent cause of heart failure. This pathology has various similarities with mitral valve prolapse in humans. And since complementary means of diagnosis aren’t always available, biomarkers like microRNA have started to be studied as a new potential way of diagnosing and treating these diseases. This project proposed to develop a trial design for extraction and measurement of microRNA concentrations, in this case miR-146a, using only blood samples, that could be used in future investigations that aim to analyze microRNA in blood samples. To this end, blood samples were collected, and echocardiographic examinations performed to 47 dogs that where then divided in four groups: control group, stage B1, B2 and C. The study was divided in two phases, the first phase took place between 2020/2021 and the second phase in 2021/2022. Till this date it was not yet possible to acquire miR-146a concentration results from the second phase samples, however the samples from the first phase of this study revealed for the first time a relation between this microRNA and myxomatous mitral valve disease in dogs. It is expected that the second phase results corroborate the first phase. Palavras-chave: Myxomatous mitral valve disease; trial design; biomarkers; miR-146a.
Descrição
Orientação: Luís Lima Lobo
Palavras-chave
MESTRADO INTEGRADO EM MEDICINA VETERINÁRIA, MEDICINA VETERINÁRIA, VETERINARY MEDICINE, VETERINÁRIA, CANÍDEOS, CANIDS, CÃES, DOGS, DOENÇA DEGENERATIVA MIXOMATOSA DA VÁLVULA MITRAL, MYXOMATOUS MITRAL VALVE DEGENERATION, PROTOCOLOS CLÍNICOS, CLINICAL PROTOCOLS, BIOMARCADORES, BIOMARKERS